Related Experiment Video
Updated: Mar 26, 2026
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
[The mechanism of progression without androgen receptor interaction in prostate cancer]
Abstract:
Recently, new generation androgen receptor (AK) targeted agents enzautamide or abiraterone etc.) has been clinically utilized in patients with castration-resistant prostate cancer (CRPC). However, metastatic CRPC has also AR-independent survival pathway which leads to lethal phenotype by either adaptation or clonal selection resistant mechanism after AR targeted therapy. There are many studies regarding the progression mechanisms without AR signal transduction, such as growth factor, anti-apoptotic factor, and PTEN/mTOR pathway and so on. Also, cancer microenvironment and cancer stem cell is a hot research area for CRPC. It is very important to repress both AR-dependent and -independent signaling pathway to improve the clinical outcome in CRPC patients. Application of the new technology, such as next generation sequencing, would be developing for the prostate cancer research, providing pre-clinical proof-of-principle as a promising approach in CRPC.
Insights
New treatments target androgen receptor (AR) pathways in castration-resistant prostate cancer (CRPC). However, AR-independent pathways drive lethal CRPC, necessitating dual-pathway inhibition for improved outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- Castration-resistant prostate cancer (CRPC) remains a significant clinical challenge.
- Emerging androgen receptor (AR)-targeted therapies like enzalutamide and abiraterone are used, but resistance develops.
- AR-independent pathways contribute to CRPC progression and lethal phenotypes.
Purpose:
- To highlight the mechanisms of AR-independent progression in CRPC.
- To emphasize the importance of targeting both AR-dependent and AR-independent pathways.
- To discuss the role of cancer microenvironment and cancer stem cells in CRPC.
Summary:
- While AR-targeted agents are improving CRPC treatment, AR-independent signaling pathways, including growth factor, anti-apoptotic factors, and the PTEN/mTOR pathway, drive therapeutic resistance.
- Research into the cancer microenvironment and cancer stem cells is crucial for understanding CRPC progression.
- Simultaneous inhibition of AR-dependent and AR-independent pathways is essential for improving clinical outcomes in CRPC patients.
Impact:
- This research underscores the need for comprehensive therapeutic strategies against CRPC.
- Advances in next-generation sequencing offer promising approaches for CRPC research and treatment development.
- Identifying and targeting AR-independent pathways could lead to more effective treatments for advanced prostate cancer.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
02:38Mitogens and the Cell Cycle
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...